Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367843 | 0.81 | BCAT2 (0.65) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL28866121 | 0.81 | BCAT2 (0.65) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL2549892 | 0.80 | KDM4E (0.50) | TSHRMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL14894712 | 0.80 | TAS1R3 (0.50) | TSHRMEN1KMT2ANPC1MAPT | |
| SCHEMBL2088683 | 0.80 | KCNQ3 (0.49) | TSHRSRD5A2KMO | |
| SCHEMBL6322177 | 0.80 | SRD5A2 (0.79) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL3184435 | 0.80 | TSHR (0.70) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL4372370 | 0.79 | BCAT2 (0.62) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL110094 | 0.78 | TSHR (0.67) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL371998 | 0.78 | TSHR (1.00) | TSHRSRD5A2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785425-B2 | 11β-hydroxyandrosta-4-ene-3-ones | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. | 2014-07-22 | — | — | US | disclosed |
| CN-101384610-B | 11 beta-hydroxyandrostan-4-en-3-ones | SUN PHARMA ADVANCED RES CO LTD | 2013-07-17 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | SUN PHARMA ADVANCE RESEARCH COMPANY (IN) | 2009-02-26 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| EP-1024806-B1 | USE OF NON-IMMUNOSUPPRESSIVE COMPOUNDS FOR PROMOTING NERVE REGENERATION | UNIV OREGON HEALTH SCIENCES (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-6734211-B1 | FOR STIMULATING NERVE CELL GROWTH IN A SUBJECT COMPRISING ADMINISTERING TO THE SUBJECT A BASTADIN COMPOUND OR ITS ANALOGS | OREGON HEALTH & SCIENCES UNIVERSITY | 2004-05-11 | — | — | US | disclosed |
| EP-1024806-A1 | USE OF NON-IMMUNOSUPPRESSIVE COMPOUNDS FOR PROMOTING NERVE REGENERATION | OREGON HEALTH SCIENCES UNIVERSITY (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999021552-A1 | USE OF NON-IMMUNOSUPPRESSIVE COMPOUNDS FOR PROMOTING NERVE REGENERATION | OREGON HEALTH SCIENCES UNIVERSITY (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | TSHR 162/4885SRD5A2 405/4885MEN1 4525/4885 |
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | HSD11B1, HSD3B1, HSD3B2 | TSHR 801/4885SRD5A2 18/4885MEN1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.